Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update

(2020) Kimberly H. Allison et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint

(2020) Miao Yu et al.   Nature Communications

CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection

(2020) Erik Wennerberg et al.   Cancer Immunology Research

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer

(2020) Rita Nanda et al.   JAMA Oncology

Body mass index and tumor infiltrating lymphocytes in triple-negative breast cancer

(2020) Giuseppe Floris et al.   JNCI-Journal of the National Cancer Institute

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

(2019) Willemijn S. M. E. Theelen et al.   JAMA Oncology

Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial

(2019) Sandra Demaria et al.   Journal for ImmunoTherapy of Cancer

Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis

(2018) F Poggio et al.   ANNALS OF ONCOLOGY

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

(2018) Hope S. Rugo et al.   CLINICAL CANCER RESEARCH

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

(2018) Carsten Denkert et al.   LANCET ONCOLOGY

The hallmarks of successful anticancer immunotherapy

(2018) Lorenzo Galluzzi et al.   Science Translational Medicine

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neo-adjuvant chemotherapy

(2018) S J Luen et al.   ANNALS OF ONCOLOGY

Radiotherapy induces responses of lung cancer to CTLA-4 blockade

(2018) Silvia C. Formenti et al.   NATURE MEDICINE

Loss of CD73 prevents accumulation of alternatively activated macrophages and the formation of prefibrotic macrophage clusters in irradiated lungs

(2017) Simone de Leve et al.   FASEB JOURNAL

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

(2017) Claire Vanpouille-Box et al.   Nature Communications

The genomic landscape of breast cancer and its interaction with host immunity

(2016) Stephen Luen et al.   BREAST

Extracellular Adenosine Production by ecto-5'-Nucleotidase (CD73) Enhances Radiation-Induced Lung Fibrosis

(2016) F. Wirsdo rfer et al.   CANCER RESEARCH

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

(2016) Fatima Cardoso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adenosine can thwart antitumor immune responses elicited by radiotherapy

(2016) Peter Vaupel et al.   STRAHLENTHERAPIE UND ONKOLOGIE

Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease

(2016) J. Liu et al.   Cancer Discovery

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

(2016) Sasha E. Stanton et al.   JAMA Oncology

Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors

(2015) Anja Derer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer

(2015) B. G. Leclerc et al.   CLINICAL CANCER RESEARCH

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions

(2015) A. Filatenkov et al.   CLINICAL CANCER RESEARCH

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Combination of Radiotherapy and Immune Checkpoint Inhibitors

(2015) Karsten A. Pilones et al.   SEMINARS IN RADIATION ONCOLOGY

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

(2014) H. Bonnefoi et al.   ANNALS OF ONCOLOGY

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Combinations of Immunotherapy and Radiation in Cancer Therapy

(2014) Ralph E. Vatner et al.   Frontiers in Oncology

Anti-CD73 therapy impairs tumor angiogenesis

(2013) Bertrand Allard et al.   INTERNATIONAL JOURNAL OF CANCER

Phase 1 Clinical Trial of Stereotactic Body Radiation Therapy Concomitant With Neoadjuvant Chemotherapy for Breast Cancer

(2013) Pierre-Yves Bondiau et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA